

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

DUAL INHIBITOR JAK-SyK “SYHX1901” OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “SYHX1901” (the “**Product**”) developed by the Group has obtained approval granted by the National Medical Products Administration to conduct clinical trials in China. The Group has submitted a number of patent applications for the Product in China and overseas.

As a dual-target inhibitor, SYHX1901 shows a relatively strong inhibitory activity with all subtypes of JAK and SyK kinases and has the potential to develop broad-spectrum treatment for autoimmune diseases. The clinical indications for this approval are rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The pre-clinical studies have shown that the Product has a high selectivity of efficacy targets, can significantly ameliorate SLE skin lesions and lower the arthritis index score, and has excellent in vivo and in vitro activities as well as good safety, providing a promising prospect of demonstrating good efficacy on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in the clinical trials.

Given the favorable results of the non-clinical studies, the Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible for the benefit of patients around the world.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 16 March 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.